Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.75 +2.9%	$1.74	$1.41 ▼ $5.01	$9.62M	1.19	26,144 shs	9,119 shs
ATHX Athersys		$0.00	$0.01 ▼ $1.99	$833K	-0.9	1.77 million shs	N/A
RDUS Radius Recycling	$29.72 +0.3%	$29.53	$10.57 ▼ $29.75	$838.45M	1	456,288 shs	338,361 shs
URGN Urogen Pharma	$13.49 +4.1%	$9.67	$3.42 ▼ $18.15	$626.14M	1.02	1.08 million shs	737,414 shs
ZFGN Zafgen	$3.20 +2.9%	$18.47	$0.62 ▼ $2.76	$119.90M	0.27	360,199 shs	516,014 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	0.00%	+4.48%	-9.79%	+2.94%	-54.78%
ATHX Athersys	0.00%	0.00%	0.00%	0.00%	-69.70%
RDUS Radius Recycling	0.00%	+0.27%	+0.20%	+2.70%	+87.15%
URGN Urogen Pharma	0.00%	0.00%	+174.19%	+31.61%	-10.13%
ZFGN Zafgen	+2.89%	+3.90%	+32.78%	+63.27%	-58.06%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	2.8377 of 5 stars	3.5	4.0	0.0	0.0	1.1	0.8	1.3
ATHX Athersys	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RDUS Radius Recycling	2.5263 of 5 stars	1.0	4.0	0.8	2.6	2.5	1.7	0.0
URGN Urogen Pharma	4.4679 of 5 stars	4.5	2.0	0.0	4.5	1.8	2.5	0.0
ZFGN Zafgen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	785.71% Upside
ATHX Athersys	0.00	N/A	N/A	N/A
RDUS Radius Recycling	2.00	Hold	$22.00	-25.98% Downside
URGN Urogen Pharma	3.00	Buy	$32.86	143.57% Upside
ZFGN Zafgen	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZFGN, URGN, ATHX, APRE, and RDUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00
5/23/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $15.00
5/22/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $3.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.45	N/A	N/A	$3.55 per share	0.49
ATHX Athersys	$146K	0.00	N/A	N/A	($1.33) per share	0.00
RDUS Radius Recycling	$2.74B	0.31	$0.73 per share	40.59	$18.73 per share	1.59
URGN Urogen Pharma	$90.40M	6.88	N/A	N/A	($0.21) per share	-64.24
ZFGN Zafgen	N/A	N/A	N/A	N/A	$1.35 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.37	N/A	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
ATHX Athersys	-$72.53M	-$2.03	N/A	N/A	N/A	N/A	N/A	-223.03%	N/A
RDUS Radius Recycling	-$266.41M	-$3.60	N/A	∞	N/A	-3.69%	-15.73%	-6.01%	N/A
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)
ZFGN Zafgen	-$45.41M	-$1.07	N/A	∞	N/A	N/A	-51.34%	-34.55%	N/A

Latest ZFGN, URGN, ATHX, APRE, and RDUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/1/2025	Q3 2025	RDUS Radius Recycling	-$0.87	-$0.39	+$0.48	-$0.59	$725.30 million	$726.99 million
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
ATHX Athersys	N/A	N/A	N/A	N/A	N/A
RDUS Radius Recycling	$0.75	2.52%	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A
ZFGN Zafgen	N/A	N/A	N/A	N/A	N/A

Latest ZFGN, URGN, ATHX, APRE, and RDUS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/26/2025	RDUS Radius Recycling	quarterly	$0.1875	2.53%	7/21/2025	7/21/2025	8/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.90	5.90
ATHX Athersys	N/A	0.06	0.06
RDUS Radius Recycling	0.85	1.85	0.88
URGN Urogen Pharma	N/A	5.65	5.47
ZFGN Zafgen	0.26	6.56	6.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
ATHX Athersys	19.35%
RDUS Radius Recycling	78.11%
URGN Urogen Pharma	91.29%
ZFGN Zafgen	70.43%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
ATHX Athersys	0.03%
RDUS Radius Recycling	4.90%
URGN Urogen Pharma	5.10%
ZFGN Zafgen	14.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
ATHX Athersys	24	61.72 million	61.70 million	No Data
RDUS Radius Recycling	3,353	28.20 million	26.82 million	Optionable
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable
ZFGN Zafgen	38	37.47 million	N/A	Not Optionable

ZFGN, URGN, ATHX, APRE, and RDUS Headlines

Recent News About These Companies

GSK/Sirtris compounds dogged by assay artifacts

May 21, 2024 | nature.comN

Tokyo Steel Manufacturing Co Ltd 5423

May 16, 2024 | morningstar.comM

Diagnosing Diabetes: Not So Simple

November 2, 2023 | medscape.comM

Do New Weight Loss Meds Mean the End of Bariatric Surgery?

October 6, 2023 | medscape.comM

Prader-Willi syndrome

August 23, 2023 | pharmaphorum.comP

The Omnipod 5 System: Trial Results From ENDO 2021

August 4, 2023 | medscape.comM

Beta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?

July 5, 2023 | medscape.comM

Oral Semaglutide Brings GLP-1s to Primary Care

May 20, 2023 | medscape.comM

Clinical Trials - Different Phases of the trial News, Research and Latest Updates

May 20, 2023 | medindia.netM

Obesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital Journal

May 12, 2023 | news.google.comN

Weight Loss and Obesity Management Market Insights With ... - Taiwan News

May 11, 2023 | news.google.comN

Global Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern Examiner

May 4, 2023 | news.google.comN

Weight Loss and Obesity Management Market May See a Big Move ... - Digital Journal

May 2, 2023 | news.google.comN

Ironwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best Stocks

May 2, 2023 | news.google.comN

The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation

April 29, 2023 | medscape.comM

Fast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape Reference

April 21, 2023 | news.google.comN

Anti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital Journal

April 20, 2023 | news.google.comN

Anti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPR

April 14, 2023 | news.google.comN

New ADA Standards: Promoting Health

April 13, 2023 | medscape.comM

New ADA Standards: Promoting Health

April 13, 2023 | medscape.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZFGN, URGN, ATHX, APRE, and RDUS Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.75 +0.05 (+2.94%)

Closing price 07/3/2025 01:56 PM Eastern

Extended Trading

$1.75 0.00 (0.00%)

As of 07/3/2025 04:43 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Athersys NASDAQ:ATHX

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

Radius Recycling NASDAQ:RDUS

$29.72 +0.09 (+0.30%)

As of 07/3/2025 03:17 PM Eastern

Radius Recycling, Inc. recycles ferrous and nonferrous metal, and manufactures finished steel products worldwide. The company acquires, processes, and recycles salvaged vehicles, rail cars, home appliances, industrial machinery, manufacturing scrap, and construction and demolition scrap. It offers recycled ferrous metal, a feedstock used in the production of finished steel products; and nonferrous products, including mixed metal joint products recovered from the shredding process, such as zorba, zurik, aluminum, copper, stainless steel, nickel, brass, titanium, lead, and high temperature alloys. The company also procures salvaged vehicles and sells serviceable used auto parts from these vehicles through its retail self-service auto parts stores. In addition, it produces various finished steel products using ferrous recycled metal and other raw materials, as well as semi-finished goods, which include billets; and finished goods consisting of rebar, coiled rebar, wire rods, merchant bars, and other specialty products. Further, the company sells catalytic converters to specialty processors that extract the nonferrous precious metals, including platinum, palladium, and rhodium; and ferrous and nonferrous recycled metal products to steel mills, foundries, refineries, smelters, wholesalers, and recycled metal processors, as well as finished steel customers, such as steel service centers, construction industry subcontractors, steel fabricators, wire drawers, and major farm and wood products suppliers. It also provides recycling and related services, including scrap brokerage, certified destruction, automotive parts recycling, railcar dismantling, and reverse logistics under 3PR brand name. Radius Recycling, Inc. was formerly known as Schnitzer Steel Industries, Inc. and changed its name to Radius Recycling, Inc. in January 2024. Radius Recycling, Inc. was founded in 1906 and is headquartered in Portland, Oregon.

Urogen Pharma NASDAQ:URGN

$13.49 +0.53 (+4.09%)

Closing price 07/3/2025 03:11 PM Eastern

Extended Trading

$13.39 -0.10 (-0.74%)

As of 07/3/2025 04:59 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

Zafgen NASDAQ:ZFGN

Zafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time